Fundraising FoxKoutif Therapeutics
Cleveland, US · Founded 2017 · Delaware LLC
Find your way into Koutif Therapeutics
Sign up to see every warm intro you have to Koutif Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Koutif Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Koutif Therapeutics develops therapeutic compounds that inhibit the inflammatory cascade by targeting the ubiquitin degradation pathway, specifically using an inhibitor of the Fbxo3 E3 ligase to degrade pro-inflammatory proteins such as TRAFs and the NLRP3 inflammasome. Its drug discovery approach is based on intellectual property licensed from the University of Pittsburgh and the U.S. Department of Veterans Affairs, aimed at treating inflammatory conditions.
Founders & leadership
Koutif Therapeutics was founded in 2017 by Rama Mallampalli and Beibei Chen.
Reported raises · per SEC filings
Form D private placements$2.6M disclosed across 1 round · 2017
▶$2.6MraisedOct 2018 · 3 investors · PharmaceuticalsRule 506(b)
- Baiju R ShahDirector
- Offering amount
- $5M
- Amount sold
- $2.6M
- First sale
- Sep 2017
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Koutif Therapeutics do?
- Koutif Therapeutics develops therapeutic compounds that inhibit the inflammatory cascade by targeting the ubiquitin degradation pathway, specifically using an inhibitor of the Fbxo3 E3 ligase to degrade pro-inflammatory proteins such as TRAFs and the NLRP3 inflammasome. Its drug discovery approach is based on intellectual property licensed from the University of Pittsburgh and the U.S. Department of Veterans Affairs, aimed at treating inflammatory conditions.
- Who founded Koutif Therapeutics?
- Koutif Therapeutics was founded by Rama Mallampalli, Beibei Chen in 2017.
- How much funding has Koutif Therapeutics raised?
- Koutif Therapeutics has disclosed $2.6M raised across 1 round.
- Where is Koutif Therapeutics headquartered?
- Koutif Therapeutics is headquartered in Cleveland, US.